The APOA1 Knockout A-549 Polyclonal Cells constitute a heterogeneous population of A-549 cells engineered via CRISPR/Cas9-mediated disruption of the APOA1 gene. This polyclonal knockout pool offers a versatile loss-of-function model for studying apolipoprotein A-I biology in a human lung adenocarcinoma epithelial background. Unlike clonal isolates, the polyclonal format preserves genetic diversity, enabling robust assessment of APOA1-dependent phenotypes across a broad cellular context. The product is provided as a polyclonal cell population, ensuring immediate utility for functional studies without the need for single-cell cloning.
The A-549 cell line, established from a pulmonary adenocarcinoma of a 58-year-old Caucasian male, is widely employed as a model system for human lung adenocarcinoma and respiratory epithelial biology. These adherent epithelial cells retain key characteristics of alveolar type II pneumocytes, including surfactant production and growth factor responsiveness. The A-549 background provides a physiologically relevant platform to investigate lipid metabolism and cholesterol homeostasis in the context of lung epithelial cells, which are increasingly recognized as active participants in lipid handling and inflammatory responses.
Apolipoprotein A-I (APOA1) is the major protein constituent of high-density lipoprotein (HDL) and plays a central role in reverse cholesterol transport. APOA1 is transcriptionally regulated by PPAR??, LXR, RXR, insulin, glucocorticoids, and HNF4??. It functions by interacting with ABCA1 to mediate cholesterol efflux from peripheral cells, forming nascent HDL particles. APOA1 activates lecithin-cholesterol acyltransferase (LCAT), promoting cholesterol esterification and HDL maturation. The mature HDL particles interact with SR-BI for selective cholesterol uptake in the liver, a process modulated by PLTP, CETP, and apoA-II. Thus, APOA1 coordinates multiple steps in cholesterol efflux and HDL metabolism, linking its function to cardiovascular health and cellular lipid balance.
In A-549 cells, APOA1 knockout impairs the expression of apolipoprotein A-I, thereby disrupting HDL biogenesis and cholesterol efflux pathways. This loss-of-function model is expected to reduce ABCA1-dependent cholesterol efflux, leading to intracellular lipid accumulation and altered cholesterol homeostasis. Given the role of A-549 cells in inflammatory signaling and surfactant metabolism, APOA1 deficiency may also influence inflammatory responses and membrane lipid composition within the lung epithelial context. The model thus provides a unique tool to dissect the intersection of lipid metabolism and epithelial cell biology in a disease-relevant cell model.
This polyclonal knockout product is ideal for investigating HDL metabolism, reverse cholesterol transport, and the cellular mechanisms underlying atherosclerosis and Tangier disease. Researchers can evaluate the impact of APOA1 disruption on cholesterol trafficking using cholesterol efflux assays, monitor lipid accumulation via Filipin or Oil Red O staining, and assess changes in gene expression by RT-qPCR and western blotting. Importantly, the model enables drug screening for compounds that restore cholesterol efflux or modulate APOA1-related pathways, such as PPAR/LXR agonists. For further information or technical support, please contact Ascent Research.
